NCT06463522

Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Beijing 302 Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 1, open label clinical trial of tumor-infiltrating lymphocytes for the treatment of patients with hepatocellular carcinoma. The purpose of this study is to assess the safety of tumor-infiltrating lymphocytes therapy in patients with hepatocellular carcinoma.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
PROCEDURE	Autologous Tumor-infiltrating Lymphocytes	Autologous Tumor-infiltrating Lymphocytes, 2.0\*10\^7/Kg, single intravenous infusion.

Timeline

• Start date: 2024-07-01
• Primary completion: 2025-07-01
• Completion: 2026-07-01
• First posted: 2024-06-17
• Last updated: 2024-08-13

Locations

1 site across 1 country: China